Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC-6004 plus Gemcitabine in Pancreatic Cancer
NCT02043288Phase 3Completed
- Sponsor
- Orient EuroPharma
- Start
- Jan 2014
- Primary completion
- Dec 2019
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of demplatin pegraglumer in pancreatic cancer (PC) (2 arms), sponsored by Orient EuroPharma. Primary endpoint: Overall Survival at 3.5 years. Started Jan 2014; status: completed.
02
Drugs
demplatin pegraglumer
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02043288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02043288.